Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US FDA Joins Chorus Of Concerns About Results Of GAIN Act

Executive Summary

It's too early to say whether program is working, FDA tell Congress; agency has awarded 147 QIDP designations, but none of 12 approved antibacterals have new mechanism of action.


Related Content

Antibiotic Guidance: Limited Populations Do Not Include Rare Infections
US Antibiotic Incentives Extended To Drugs That Prevent Or Diagnose Infections
New Report Calls For Pushing And Pulling In Global Fight Against Superbugs
Antibiotic Spring? Regulatory Incentives Spur Activity – And Maybe Medical Advances
Antibiotics Pipeline Is Lively, But Sponsors Are Fragile
Antibiotic Development: Limited Population Pathway In US Removes Barrier
Antibiotic Development: US FDA Needs Draft Guidance On QIDP Designation, GAO Says
Antibiotic Development: ‘Wildcard Exclusivity’ Proposal Returns
Value-Based Reimbursement For Antibiotics Gets Skeptical Reception
GAIN Begins (Part 1): FDA Completes Turnaround On Antibiotic R&D





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts